Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial
University of Southern California · Queen's University · +12 more institutions
Indexed incrossrefpubmed
Abstract
Background
Effective, well-tolerated oral psoriasis treatments are needed.
Objective
To compare the efficacy and safety of deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, versus placebo and apremilast in adults with moderate to severe plaque psoriasis.
Citation impact
338
total citations
- FWCI
- 25.55
- Percentile
- 100%
- References
- 18
Citations per year
Authors
16- AWApril W. ArmstrongCorresponding
University of Southern California
- MGMelinda Gooderham
Queen's University, Probity Medical Research
- RBRichard B. Warren
Salford Royal NHS Foundation Trust, University of Manchester, NIHR Manchester Biomedical Research Centre
- KPKim Papp
Probity Medical Research
- BSBruce Strober
Yale University, Central Dermatology
Topics & keywords
Topics
Keywords
- Medicine
- Apremilast
- Placebo
- Psoriasis
- Double blinded
- Randomized controlled trial
- Plaque psoriasis
- Internal medicine
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.